Takeda Pharmaceutical Company Profile (OTCMKTS:TKPYY)

About Takeda Pharmaceutical

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TKPYY
  • CUSIP:
Key Metrics:
  • Previous Close: $23.25
  • 50 Day Moving Average: $23.36
  • 200 Day Moving Average: $22.66
  • 52-Week Range: $1,563,644,000.00 - $20.32
  • Trailing P/E Ratio: 24.07
  • P/E Growth: 0.00
  • Market Cap: $35.70B
  • Outstanding Shares: 1,563,644,000
  • Beta: 0.29
  • Net Margins: 8.87%
  • Return on Equity: 10.64%
  • Return on Assets: 5.45%
  • Debt-to-Equity Ratio: 0.40%
  • Current Ratio: 1.79%
  • Quick Ratio: 1.50%
Additional Links:
Companies Related to Takeda Pharmaceutical:

Analyst Ratings

Consensus Ratings for Takeda Pharmaceutical (OTCMKTS:TKPYY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2014$0.21ViewN/AView Earnings Details
2/5/2014Q4$0.29ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No insider trades for this company have been tracked by MarketBeat.com


Latest Headlines for Takeda Pharmaceutical (OTCMKTS:TKPYY)
finance.yahoo.com logoTakeda Pharma upgraded by UBS (OTCMKTS:TKPYY)
finance.yahoo.com - October 21 at 11:18 AM
seekingalpha.com logoSucampo Pharmaceuticals Q3: Surprise Likely (OTCMKTS:TKPYY)
seekingalpha.com - October 18 at 10:05 AM
finance.yahoo.com logoTakeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th International Symposium on Hodgkin Lymphoma (ISHL) (OTCMKTS:TKPYY)
au.finance.yahoo.com - October 18 at 10:05 AM
nasdaq.com logoTiGenix: Cx601 For Perianal Fistula Gets Orphan Drug Designation In Switzerland (OTCMKTS:TKPYY)
www.nasdaq.com - October 17 at 7:33 PM
seekingalpha.com logoMyovant Sciences IPO Has Nothing But IP (OTCMKTS:TKPYY)
seekingalpha.com - October 17 at 7:33 PM
thestreet.com logoVedolizumab presentations include real-world and post-marketing safety data (OTCMKTS:TKPYY)
www.thestreet.com - October 17 at 7:33 PM
finance.yahoo.com logoTakeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting (OTCMKTS:TKPYY)
finance.yahoo.com - October 17 at 9:56 AM
finance.yahoo.com logoExperiment in monkeys raises hopes of "functional cure" for HIV (OTCMKTS:TKPYY)
finance.yahoo.com - October 13 at 7:53 PM
News IconTiny Crescendo Biologics Hammers Out $790 Million Immuno-Oncology Deal With Biotech Giant Takeda (OTCMKTS:TKPYY)
www.biospace.com - October 11 at 10:26 AM
News IconCrescendo, Takeda Reach Immuno-Oncology Deal (OTCMKTS:TKPYY)
www.pharmalive.com - October 10 at 7:09 PM
finance.yahoo.com logoCrescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m (OTCMKTS:TKPYY)
au.finance.yahoo.com - October 10 at 9:40 AM
marketwatch.com logoTakeda and Crescendo Biologics enter into cancer drug development partnership (OTCMKTS:TKPYY)
www.marketwatch.com - October 10 at 9:39 AM
finance.yahoo.com logoEnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology (OTCMKTS:TKPYY)
finance.yahoo.com - October 9 at 6:55 PM
finance.yahoo.com logoTakeda Donates $100,000 To Local, Regional Non-Profits (OTCMKTS:TKPYY)
finance.yahoo.com - October 7 at 7:20 PM
News IconIntra-Cellular Therapies Plunges After Schizophrenia Study Fails (OTCMKTS:TKPYY)
magseriesusa.net - September 29 at 7:36 PM
capitalcube.com logoETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : September 29, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - September 29 at 9:58 AM
finance.yahoo.com logoAdditional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis (OTCMKTS:TKPYY)
finance.yahoo.com - September 28 at 7:27 PM
finance.yahoo.com logo3:17 pm Takeda Pharma announces additional interim data on the long-term use of vedolizumab in patients with ulcerative colitis and Crohn's disease was published in the Journal of Crohn's & Colitis (OTCMKTS:TKPYY)
finance.yahoo.com - September 28 at 7:27 PM
News IconLigand Pharma Dives After Out-Licensed Drug Misses Study Goal (OTCMKTS:TKPYY)
www.talkmarkets.com - September 28 at 9:59 AM
thestreet.com logoSynergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program (OTCMKTS:TKPYY)
www.thestreet.com - September 28 at 9:59 AM
marketrealist.com logoStrong Brand Positioning Expected to Strengthen Teva’s Position (OTCMKTS:TKPYY)
marketrealist.com - September 27 at 7:37 PM
bloomberg.com logoTakeda's Biotech M&A Menu Is Long, Complex (OTCMKTS:TKPYY)
www.bloomberg.com - September 21 at 7:09 PM
finance.yahoo.com logoTakeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in Central Nervous System (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 21 at 7:01 AM
finance.yahoo.com logoTakeda and Zydus Cadila partner to address the global threat of Chikungunya (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 20 at 9:13 AM
seekingalpha.com logoEuropean Ad Comm backs Takeda's Ninlaro in multiple myeloma (OTCMKTS:TKPYY)
seekingalpha.com - September 16 at 11:17 AM
finance.yahoo.com logoFavorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology (OTCMKTS:TKPYY)
finance.yahoo.com - September 16 at 11:17 AM
thestreet.com logoWill Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals? (OTCMKTS:TKPYY)
www.thestreet.com - September 14 at 12:01 PM
finance.yahoo.com logoTakeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 12 at 9:48 AM
finance.yahoo.com logoTakeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003) (OTCMKTS:TKPYY)
au.finance.yahoo.com - September 7 at 11:30 AM
ft.com logo[$$] Takeda signals global ambitions with dengue vaccine trial (OTCMKTS:TKPYY)
www.ft.com - September 7 at 11:30 AM
finance.yahoo.com logoTakeda Launches Wearable Digital Technology Pilot Program to Support Patients and Healthcare Providers with Inflammatory Bowel Disease Management (OTCMKTS:TKPYY)
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logo6 Drug Stocks in Focus as Zika Virus Fear Spreads (OTCMKTS:TKPYY)
finance.yahoo.com - September 6 at 9:35 AM
finance.yahoo.com logoTakeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 31 at 9:55 AM
finance.yahoo.com logoTakeda Announces Bold, New Access to Medicines Strategy (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 27 at 9:46 AM
capitalcube.com logoETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : August 24, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - August 24 at 7:34 PM
finance.yahoo.com logoTakeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 8 at 9:58 AM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 5, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - August 5 at 10:52 AM
finance.yahoo.com logoTakeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma (OTCMKTS:TKPYY)
au.finance.yahoo.com - August 1 at 6:59 AM
News IconTakeda to Now Focus on Three Therapeutic Areas (OTCMKTS:TKPYY)
www.pharmalive.com - July 29 at 8:03 PM
capitalcube.com logoETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : July 29, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - July 29 at 12:52 PM
bloomberg.com logoJapan’s Takeda Sees $725 Million in Costs From R&D Revamp (OTCMKTS:TKPYY)
www.bloomberg.com - July 29 at 4:38 AM
finance.yahoo.com logoTakeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance (OTCMKTS:TKPYY)
au.finance.yahoo.com - July 29 at 2:00 AM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - July 26 at 9:29 AM
bloomberg.com logoTakeda Said to Explore Sale of Chemicals Unit to Raise Cash (OTCMKTS:TKPYY)
www.bloomberg.com - July 21 at 7:49 AM
bloomberg.com logoStock Picker Wahei Takeda, Dubbed Japan’s Buffett, Dies at 83 (OTCMKTS:TKPYY)
www.bloomberg.com - July 21 at 4:35 AM
finance.yahoo.com logoTakeda Aims To Raise $500,000 for Team Challenge for Crohn's & Colitis (OTCMKTS:TKPYY)
finance.yahoo.com - July 15 at 1:00 PM
finance.yahoo.com logoTakeda and the Crohn's & Colitis Foundation of America Partner to Introduce 'IBD Unmasked' A First-of-its-Kind Awareness Campaign (OTCMKTS:TKPYY)
finance.yahoo.com - July 13 at 8:00 AM
finance.yahoo.com logoIBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community (OTCMKTS:TKPYY)
finance.yahoo.com - July 13 at 4:55 AM
seekingalpha.com logoTakeda nabs ex-U.S. rights to investigational stem cell treatment for Crohn's-related fistulas (OTCMKTS:TKPYY)
seekingalpha.com - July 6 at 9:32 AM
finance.yahoo.com logoTakeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma (OTCMKTS:TKPYY)
au.finance.yahoo.com - July 6 at 8:00 AM


Takeda Pharmaceutical (OTCMKTS:TKPYY) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by MarketBeat.com Staff